Estrogen Use in Protection From Cognitive Decline

Completed

Conditions studied: Aging, Menopause

In brief

This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.

Key facts

Study ID

NCT00097058

Run by

Stanford University

People needed

71

Starts

2003-08-01

Expected to finish

2014-11-01

Last updated by the study team

2014-11-19

Who can join

Age: 45 and older, up to 65. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women between the ages of 45 and 65
• Currently on hormone replacement
• One year or more post complete cessation of menses
• Willing to sign the Human Subject Protection Consent form prior to enrollment in the study
• Willing to be randomized to continue or discontinue estrogen therapy
• Adequately visually and auditorially acute to allow neuropsychological testing
• Beyond 8 years of educational achievement to allow adequate neuropsychological testing
• Willing to undergo brain imaging
• At risk for cognitive decline, as defined by one or more of the following: Personal or family history of mood disorder, Hypothyroidism, Diabetes, Family history of Alzheimer's, APOE-4 allele

You may not qualify if…

• Diagnosis of possible or probable Alzheimer's disease or dementia
• Cerebrovascular disease or uncontrolled hypertension (systolic BP >170 or diastolic BP >100)
• History of myocardial infarction within previous year or unstable heart disease
• History of significant liver disease, pulmonary disease, or current cancer
• Contraindication for MRI (metal in body, claustrophobia, etc.)

Where it is running

• Stanford University School of Medicine, Dept. of Psychiatry and Behavioral Sciences — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.